GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » China Biotech Services Holdings Ltd (HKSE:08037) » Definitions » COGS-to-Revenue

China Biotech Services Holdings (HKSE:08037) COGS-to-Revenue : 0.00 (As of Dec. 2024)


View and export this data going back to 2004. Start your Free Trial

What is China Biotech Services Holdings COGS-to-Revenue?

China Biotech Services Holdings's Cost of Goods Sold for the three months ended in Dec. 2024 was HK$0.00 Mil. Its Revenue for the three months ended in Dec. 2024 was HK$0.00 Mil.

China Biotech Services Holdings's COGS to Revenue for the three months ended in Dec. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. China Biotech Services Holdings's Gross Margin % for the three months ended in Dec. 2024 was N/A%.

China Biotech Services Holdings COGS-to-Revenue Historical Data

The historical data trend for China Biotech Services Holdings's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Biotech Services Holdings COGS-to-Revenue Chart

China Biotech Services Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.48 0.43 0.41 0.84 1.07

China Biotech Services Holdings Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Dec24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.77 1.62 2.38 - -

China Biotech Services Holdings COGS-to-Revenue Calculation

China Biotech Services Holdings's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=75.449 / 70.509
=1.07

China Biotech Services Holdings's COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Biotech Services Holdings  (HKSE:08037) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

China Biotech Services Holdings's Gross Margin % for the three months ended in Dec. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

China Biotech Services Holdings COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of China Biotech Services Holdings's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

China Biotech Services Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » China Biotech Services Holdings Ltd (HKSE:08037) » Definitions » COGS-to-Revenue
Comparable Companies
HKSE:02427 HKSE:08225 HKSE:00928 HKSE:08247 HKSE:09960 HKSE:06667 HKSE:02325 TMO DHR XSWX:LONN IDXX A SHSE:603259 IQV MTD NTRA WAT LH DGX XPAR:BIM
Traded in Other Exchanges
N/A
Address
255-257 Gloucester Roaad, Suites 1904-05A, 19th Floor, Sino Plaza, Causeway Bay, Hong Kong, HKG
Website
http://www.cbshhk.com
China Biotech Services Holdings Ltd is an investment holding company. It operates through five segments: Pharmaceutical Products, Medical and Health-Related Services, Immunotherapy, Insurance brokerage, BNCT and Others. It derives prime revenue from the Medical and health related services segment which involves the provision of medical laboratory testing and health check services. The group has a business presence in Hong Kong and the PRC, of which key revenue is generated from Hong Kong.
Executives
Guoyuan International Holdings Limited 2201 Interest of corporation controlled by you
Guoyuan Securities Co., Ltd. 2201 Interest of corporation controlled by you
Guoyuan Securities Investment (hong Kong) Limited 2101 Beneficial owner
Genius Earn Limited 2201 Interest of corporation controlled by you
Genius Lead Limited 2101 Beneficial owner
Liu Xiaolin 2101 Beneficial owner
Richlane Ventures Limited 2101 Beneficial owner
Ko Chun Shun, Johnson 2201 Interest of corporation controlled by you

China Biotech Services Holdings Headlines

No Headlines